149 related articles for article (PubMed ID: 33523584)
61. Prognostic and functional role of subtype-specific tumor-stroma interaction in breast cancer.
Merlino G; Miodini P; Callari M; D'Aiuto F; Cappelletti V; Daidone MG
Mol Oncol; 2017 Oct; 11(10):1399-1412. PubMed ID: 28672102
[TBL] [Abstract][Full Text] [Related]
62. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
63. A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype.
Cheng Q; Chang JT; Gwin WR; Zhu J; Ambs S; Geradts J; Lyerly HK
Breast Cancer Res; 2014 Jul; 16(4):407. PubMed ID: 25060555
[TBL] [Abstract][Full Text] [Related]
64. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
[TBL] [Abstract][Full Text] [Related]
65. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients.
Ankney JA; Xie L; Wrobel JA; Wang L; Chen X
BMC Med Genomics; 2019 May; 12(1):78. PubMed ID: 31146747
[TBL] [Abstract][Full Text] [Related]
66. In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer.
Rojas K; Baliu-Piqué M; Manzano A; Saiz-Ladera C; García-Barberán V; Cimas FJ; Pérez-Segura P; Pandiella A; Győrffy B; Ocana A
Cell Oncol (Dordr); 2021 Jun; 44(3):569-580. PubMed ID: 33469836
[TBL] [Abstract][Full Text] [Related]
67. The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes.
El Ansari R; Craze ML; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Br J Cancer; 2018 Apr; 118(8):1115-1122. PubMed ID: 29545595
[TBL] [Abstract][Full Text] [Related]
68.
Qu S; Liu J; Wang H
Front Immunol; 2021; 12():648416. PubMed ID: 33889156
[TBL] [Abstract][Full Text] [Related]
69. Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma.
Canevari RA; Marchi FA; Domingues MA; de Andrade VP; Caldeira JR; Verjovski-Almeida S; Rogatto SR; Reis EM
Tumour Biol; 2016 Oct; 37(10):13855-13870. PubMed ID: 27485113
[TBL] [Abstract][Full Text] [Related]
70. High expression of the vacuole membrane protein 1 (VMP1) is a potential marker of poor prognosis in HER2 positive breast cancer.
Amirfallah A; Arason A; Einarsson H; Gudmundsdottir ET; Freysteinsdottir ES; Olafsdottir KA; Johannsson OT; Agnarsson BA; Barkardottir RB; Reynisdottir I
PLoS One; 2019; 14(8):e0221413. PubMed ID: 31442252
[TBL] [Abstract][Full Text] [Related]
71. Immune gene expression profiling reveals heterogeneity in luminal breast tumors.
Zhu B; Tse LA; Wang D; Koka H; Zhang T; Abubakar M; Lee P; Wang F; Wu C; Tsang KH; Chan WC; Law SH; Li M; Li W; Wu S; Liu Z; Huang B; Zhang H; Tang E; Kan Z; Lee S; Park YH; Nam SJ; Wang M; Sun X; Jones K; Zhu B; Hutchinson A; Hicks B; Prokunina-Olsson L; Shi J; Garcia-Closas M; Chanock S; Yang XR
Breast Cancer Res; 2019 Dec; 21(1):147. PubMed ID: 31856876
[TBL] [Abstract][Full Text] [Related]
72. Clinical significance and immunogenomic landscape analyses of the immune cell signature based prognostic model for patients with breast cancer.
Wang S; Xiong Y; Zhang Q; Su D; Yu C; Cao Y; Pan Y; Lu Q; Zuo Y; Yang L
Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33302293
[TBL] [Abstract][Full Text] [Related]
73. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
[TBL] [Abstract][Full Text] [Related]
74. Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity.
Wolf DM; Lenburg ME; Yau C; Boudreau A; van 't Veer LJ
PLoS One; 2014; 9(2):e88309. PubMed ID: 24516633
[TBL] [Abstract][Full Text] [Related]
75. Interferon-Stimulated Genes Are Involved in Cross-resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer.
Post AEM; Smid M; Nagelkerke A; Martens JWM; Bussink J; Sweep FCGJ; Span PN
Clin Cancer Res; 2018 Jul; 24(14):3397-3408. PubMed ID: 29661777
[No Abstract] [Full Text] [Related]
76. A five-gene signature is a prognostic biomarker in pan-cancer and related with immunologically associated extracellular matrix.
Yu C; You M; Zhang P; Zhang S; Yin Y; Zhang X
Cancer Med; 2021 Jul; 10(13):4629-4643. PubMed ID: 34121340
[TBL] [Abstract][Full Text] [Related]
77. The Expression Level of
Masuda T; Noda M; Kitagawa A; Hu Q; Fujii A; Ito S; Kosai K; Ando Y; Matsumoto Y; Ohtsu H; Uchida H; Ohno S; Mimori K
Anticancer Res; 2020 Jul; 40(7):3733-3742. PubMed ID: 32620612
[TBL] [Abstract][Full Text] [Related]
78. Identification of DRP1 as a prognostic factor correlated with immune infiltration in breast cancer.
Liu B; Fan Y; Song Z; Han B; Meng Y; Cao P; Tan K
Int Immunopharmacol; 2020 Dec; 89(Pt B):107078. PubMed ID: 33049497
[TBL] [Abstract][Full Text] [Related]
79. Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers.
Green AR; Aleskandarany MA; Ali R; Hodgson EG; Atabani S; De Souza K; Rakha EA; Ellis IO; Madhusudan S
Cancer Immunol Res; 2017 Apr; 5(4):292-299. PubMed ID: 28254786
[TBL] [Abstract][Full Text] [Related]
80. A matrisome RNA signature from early-pregnancy mouse mammary fibroblasts predicts distant metastasis-free breast cancer survival in humans.
Ibrahim AM; Bilsland A; Rickelt S; Morris JS; Stein T
Breast Cancer Res; 2021 Sep; 23(1):90. PubMed ID: 34565423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]